semaglutide and inflammation reduction might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? Mechanism of Semaglutide in MASLD

Understanding your genetic risk profile and peptide sensitivity helps optimize medication selection before you start, potentially reducing trial-and-error adjustments

Research suggests doing so can reduce post-meal glucose spikes by as much as 75%, he says

A total of 670 (25%) of the 2713 TRESIBA-treated patients with type 2 diabetes were 65 years or older and 80 (3%) were 75 years or older

So I call them synthetic incretins

Preclinical data on the efficacy of GLP-1RAs seem to be quite convincing, while clinical research data are still limited

The result is greater improvement in insulin sensitivity than either medication provides alone